# US 2013/0296274 A1 · Pyrrolidinones as metap-2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296274 A1
- Document ID: US20130296274A1
- Status: Published application
- Kind: A1
- Application number: 13/878,574
- Filed: 2011-09-14
- Published: 2013-11-07
- Earliest claimed: 2010-10-13
- Assignees: Merck Patent GmbH
- Inventors: Timo Heinrich; Frank Zenke; Michel Calderini; Djordje Musil
- Web page: https://patentgrep.com/patent/US20130296274A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/4025: not condensed and containing further heterocyclic rings, e.g. cromakalim
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/433: Thidiazoles
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/10: Anti-acne agents
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/277: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 405/14: containing three or more hetero rings
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 413/10: linked by a carbon chain containing aromatic rings
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07F 5/025: {Boronic and borinic acid compounds}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Compounds of the formula I in which R1, R2, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.

## Claims

### Claim 1

Compounds of the formula I
in which
R1 denotes [C(R4)2]nAr1, (CH2)nHet, (CH2)nCyc,
or A,
R2 denotes C(R4)2]nAr2, CH[B(OH)2]CH2Het,
(CH2)nHet, (CH2)nCyc, CH(C≡CH)phenyl or A,
R3 denotes OH, Hal, NH2, CN, CF3, CHF2 or N3,
R4 denotes H or alkyl having 1, 2, 3 or 4 C atoms,
R2 and R4 together also denote alkylene having 2, 3, 4 or 5 C atoms, where one CH2 group may also be replaced by NH, NA, N—COA, N—(CH2)nAr3, N—(CH2)nHet2, CH-A, CH—O—(CH2)nAr3, N—SO2A or O
and/or may be substituted by A,
Ar1 denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHSO2A, COA, CHO, Het1, SO2NH2 and/or SO2A,
Ar2 denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHSO2A, COA, CHO, Het1, SO2NH2 and/or SO2A,
Ara denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA and/or A,
Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, COOH, COOA, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, NHCOA, NHSO2A, COA, CHO, Het1, SO2NH2, SO2A and/or ═O,
Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, and/or O and/or S atoms which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH2, NHA, NA2, NO2, CN, COOH and/or COOA,
Het2 denotes pyridyl, pyrimidinyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl or thiadiazole,
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7H atoms may be replaced by F, Cl, Br, OH, CHO, COA, COOA, CN, CONA2, CONHA and/or CONH2,
and/or in which one or two non-adjacent CH and/or CH2 groups may be replaced by O, N and/or NR4,
or Cyc,
Cyc denotes cyclic alkyl having 3-7 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 2 (depends on 1)

Compounds according to claim 1 in which
R1 denotes phenyl, benzyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, CN, NHCOA, NHSO2A, SO2A and/or CONH2;
A or (CH2)nHet,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 3 (depends on 1)

Compounds according to claim 1 in which
R2 denotes [C(R4)2]nAr2, CH[B(OH)2]CH2Het, (CH2)nCyc,
CH(C≡CH)phenyl, A or (CH2)nHet,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 4 (depends on 1)

Compounds according to claim 1 in which
R3 denotes OH, N3, NH2 or F,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 5 (depends on 1)

Compounds according to claim 1 in which
Het denotes pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, indolyl, dihydroindolyl, benzofuranyl, dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl, chromanyl, piperazinyl, morpholinyl, tetrahydropyranyl, quinolinyl, isoquinolinyl, isoindolyl, dihydroquinolinyl, dihydroisoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, purinyl, naphthyridinyl, pyrimidinyl, indazolyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]pyridinyl, 1,3-benzodioxolyl, benzoxazolyl, piperidin-1-yl, pyrrolidin-1-yl, 1,2-oxazinan-2-yl, 1,2,5-oxadiazinan-2-yl, 1,3-oxazinan-3-yl or hexahydropyrimidinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, OA, COOA, COA, CHO, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2A, NHSO2A, ═O and/or Het1,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 6 (depends on 1)

Compounds according to claim 1 in which
Het1 denotes pyridazinyl, pyrazolyl, pyridyl, piperazinyl, morpholinyl, pyrimidinyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, piperidin-1-yl, pyrrolidin-1-yl, tetrahydropyranyl, 1,2-oxazinan-2-yl, 1,2,5-oxadiazinan-2-yl, 1,3-oxazinan-3-yl or hexahydropyrimidinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A and/or OA,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 7 (depends on 1)

Compounds according to claim 1 in which
R1 denotes phenyl, benzyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by Hal, CN, NHCOA, NHSO2A, SO2A and/or CONH2;
A or (CH2)nHet,
R2 denotes [C(R4)2]nAr2, (CH2)nCyc, CH[B(OH)2]CH2Het,
CH(C≡CH)phenyl, A or (CH2)nHet,
R3 denotes OH, N3, NH2 or F,
R4 denotes H or alkyl having 1, 2, 3 or 4 C atoms,
R2 and R4 together also denote alkylene having 2, 3, 4 or 5 C atoms, where one CH2 group may also be replaced by NH, NA, N—COA, N—(CH2)nAr3, N—(CH2)nHet2, CH-A, CH—O—(CH2)nAr3, N—SO2A or O
and/or may be substituted by A,
Het denotes pyridazinyl, pyrazolyl, benzimidazolyl, pyridyl, dibenzofuranyl, carbazolyl, indolyl, dihydroindolyl, benzofuranyl, dihydrobenzofuranyl, 2,3-dihydrobenzo-1,4-dioxinyl, chromanyl, piperazinyl, morpholinyl, tetrahydropyranyl, quinolinyl, isoquinolinyl, isoindolyl, dihydroquinolinyl, dihydroisoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, purinyl, naphthyridinyl, pyrimidinyl, indazolyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, benzothiazolyl, imidazo[1,2-a]-pyridinyl, 1,3-benzodioxolyl, benzoxazolyl, piperidin-1-yl, pyrrolidin-1-yl, 1,2-oxazinan-2-yl, 1,2,5-oxadiazinan-2-yl, 1,3-oxazinan-3-yl or hexahydropyrimidinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A, OA, COOA, COA, CHO, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2A, NHSO2A, ═O and/or Het1,
Het1 denotes pyridazinyl, pyrazolyl, pyridyl, piperazinyl, morpholinyl, pyrimidinyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazole, piperidin-1-yl, pyrrolidin-1-yl, tetrahydropyranyl, 1,2-oxazinan-2-yl, 1,2,5-oxadiazinan-2-yl, 1,3-oxazinan-3-yl or hexahydropyrimidinyl, each of which is unsubstituted or mono-, di- or trisubstituted by A and/or OA,
Het2 denotes pyridyl, pyrimidinyl, furyl, thienyl, imidazolyl, pyrrolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl or thiadiazole,
A denotes unbranched or branched alkyl having 1-10 C atoms, in which 1-7H atoms may be replaced by F, Cl, Br, OH, CHO, COA, COOA, CN, CONA2, CONHA and/or CONH2,
and/or in which one or two non-adjacent CH and/or CH2 groups may be replaced by O, N and/or NR4,
or Cyc,
Ar2 denotes phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by A, Hal, CN, OH and/or OA,
Ar3 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OH, OA and/or A,
Cyc denotes cyclic alkyl having 3-7 C atoms,
Hal denotes F, Cl, Br or I,
n denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 8 (depends on 1)

Compounds according to claim 1, selected from the group
Compound
No.
Structure/name
“A1”
“A2”
“A3”
“A4”
“A5”
“A6”
“A7”
“A8”
“A9”
“A10”
“A11”
“A12”
“A13”
“A14”
“A15”
“A16”
“A17”
“A18”
“A19”
“A20”
“A21”
“A22”
“A23”
“A24”
“A25”
“A26”
“A27”
“A28”
“A29”
“A30”
“A31”
“A32”
“A33”
“A34”
“A35”
“A36”
“A37”
“A38”
“A39”
“A40”
“A41”
“A42”
“A43”
“A44”
“A45”
“A46”
“A47”
“A48”
“A49”
“A50”
“A51”
“A52”
“A53”
“A54”
“A55”
“A56”
“A57”
“A58”
“A59”
“A60”
“A61”
“A62”
“A63”
“A64”
“A65”
“A66”
“A67”
“A68”
“A69”
“A70”
“A71”
“A72”
“A73”
“A74”
“A75”
“A76”
“A77”
“A78”
“A79”
“A80”
“A81”
“A82”
“A83”
“A84”
“A85”
“A86”
“A87”
“A88”
“A89”
“A90”
“A91”
“A91a”
(S)-3-Amino-2-oxo-1-phenylpyrrolidine-3-
carboxylic acid (3-chloro-5-fluorobenzyl) amide
“A92”
“A93”
“A94”
“A95”
“A96”
“A97”
“A98”
“A99”
“A100”
“A101”
“A102”
“A103”
“A104”
“A105”
“A106”
“A107”
“A108”
“A109”
“A110”
“A111”
“A112”
“A113”
“A114”
“A115”
“A116”
“A117”
“A118”
“A119”
“A120”
“A150”
3-Azido-2-oxo-1-phenylpyrrolidine-3-
carboxylic acid (3-chloro-5-fluorobenzyl) amide
“A151”
3-Amino-2-oxo-1-phenylpyrrolidine-3-
carboxylic acid (3-chloro-5-fluorobenzyl) amide
“A162”
“A163”
“A164”
“A165”
“A166”
“A167”
“A168”
“A169”
“A170”
“A171”
“A172”
“A173”
“A174”
“A175”
“A176”
“A177”
“A178”
“A179”
“A180”
“A181”
“A182”
“A183”
“A184”
“A185”
“A186”
“A187”
“A188”
“A189”
“A190”
“A191”
“A192”
“A193”
“A194”
“A195”
“A196”
“A197”
“A198”
“A199”
“A200”
“A201”
“A202”
“A203”
“A204”
“A205”
“A206”
“A207”
“A208”
“A209”
“A210”
“A211”
“A212”
“A213”
“A214”
“A215”
“A216”
“A217”
“A218”
“A219”
“A220”
“A221”
“A222”
“A223”
“A224”
“A225”
“A226”
“A227”
“A228”
“A229”
“A230”
“A231”
“A232”
“A233”
“A234”
“A235”
“A236”
“A237”
“A238”
“A239”
“A240”
“A241”
“A242”
“A243”
“A244”
“A245”
“A246”
“A247”
“A248”
“A249”
“A250”
“A251”
“A252”
“A253”
“A254”
“A255”
“A256”
“A257”
“A258”
“A259”
“A260”
“A261”
“A262”
“A263”
“A264”
“A265”
“A266”
“A267”
“A268”
“A269”
“A270”
“A271”
“A272”
“A273”
“A274”
“A275”
“A276”
“A277”
“A278”
“A279”
“A280”
“A281”
“A282”
“A283”
“A284”
“A285”
“A286”
“A287”
“A288”
“A289”
“A290”
“A291”
“A292”
“A293”
“A294”
“A295”
“A296”
“A297”
“A298”
“A299”
“A300”
“A301”
“A302”
“A303”
“A304”
“A305”
“A306”
“A307”
“A308”
“A309”
“A310”
“A311”
“A312”
“A313”
“A314”
“A315”
“A316”
“A317”
“A318”
“A319”
“A320”
“A321”
“A322”
“A323”
“A324”
“A325”
“A326”
“A327”
“A328”
“A329”
“A330”
“A331”
“A332”
“A333”
“A334”
“A335”
“A336”
“A337”
“A338”
“A339”
“A340”
“A341”
“A342”
“A343”
“A344”
“A345”
“A346”
and pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

### Claim 9 (depends on 1)

Process for the preparation of compounds of the formula I according to claim 1 and pharmaceutically usable salts, tautomers and stereoisomers thereof, characterised in that
a) a compound of the formula II
in which R1 and R3 have the meanings indicated in for formula I,
and L denotes Cl, Br, I or a free or reactively functionally modified OH group,
is reacted with a compound of the formula III
R2—NHR4 III
in which R2 and R4 have the meanings indicated in for formula I, or
b) for the preparation of compounds of the formula I in which R3 denotes OH,
a compound of the formula IV
in which R1, R2 and R4 have the meanings indicated in for formula I,
is oxidised,
or
c) a radical R3 is converted into another radical R3 by replacing an OH group with a halogen atom,
or replacing a halogen atom with N3,
and/or
a base or acid of the formula I is converted into one of its salts.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising at least one compound of the formula I according to claim 1 and/or pharmaceutically usable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and one or more excipients and/or adjuvants.

### Claim 11 (depends on 1)

A method for the treatment of tumours, tumour metastases, proliferative diseases of the mesangial cells, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularisation, psoriasis, ocular neovascularisation, osteoporosis, diabetes and obesity, lymphoid leukaemia, lymphoma, malaria and prostate hypertrophy, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

### Claim 12 (depends on 11)

A method according to claim 11, where the tumour disease is selected from the group of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx, the lung, the skin, monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glioblastoma, breast carcinoma, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma,

### Claim 13 (depends on 11)

A method according to claim 11, wherein a tumor is treated, and where the effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.

### Claim 14 (depends on 11)

A method according to claim 11, wherein a tumor is treated, and where the effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitors.
